warfarin dose and the pharmacogenomics of cyp2c9 and vkorc1 - rationale and perspectives

Thromb Res. ;(1) Epub Dec Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Yin T(1), Miyata T. Author information: (1)National Cardiovascular Center Research Institute, Suita, Osaka, Japan. Warfarin is the most widely prescribed oral anticoagulant. Warfarin is the most widely prescribed oral anticoagulant, but there is greater than fold interindividual variability in the dose required to attain a therapeutic response. Information from pharmacogenomics, the study of the interaction of an individual's genotype and drug response, can help optimize drug efficacy while. Dec 11, - Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 Rationale and perspectives. ?. Tong Yin. 1., Toshiyuki Miyata?. National Cardiovascular Center Research Institute, Suita, Osaka, Japan. Received 28 August ; received in revised form 16 October ; accepted 17 October. Information from pharmacogenomics, the study of the interaction of an individual's genotype and drug response, can help optimize drug efficacy while minimizing adverse drug reactions. Pharmacogenetic Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Tong Sin Yin. Dec 19, - Warfarin is the most widely prescribed oral anticoagulant, but there is greater than fold interindividual variability in the dose required to attain a therapeutic response. Information from Warfarin dose and the pharmacogenomics of CYP2C9 and VKORCRationale and perspectives. Article Literature. and CYP2C9 variants influencing warfarin dose requirements in the. Hispanic population. A total of patients were Studies related to Pharmacogenomics Testing in Warfarin5,6, Author/Year. Gong et al. Palacio et al. . dose and the Pharmacogenomics of. CYP2C9 and VKORC1- Rationale and Perspectives. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clinical Pharmacology and Therapeutics ; Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1: rationale and perspectives. Thrombosis Research Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res ; (1): 1 Anonymous. Genetic help for a blood-thinner balancing act? There's little evidence yet that a genetic test improves the safety of warfarin. Harv Heart Lett ; 18(4): 12. Understanding the pharmacogenetic approach to warfarin dosing. Heart Fail Rev. ; 3. Yin T, Miyata T. Warfarin dose and the Pharmacogenomics of CYP2C9 and VKORC1 *rationale and perspectives. Throml) Res. ; 1 0. 4. Wen MS, Lee M, Chen J], et al. Prospective study of warfarin dosage. Hum Genet ;(1) Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 rationale and perspectives. Thromb Res ;(1):1 Anonymous. Genetic help for a blood-thinner balancing act? There's little evidence yet that a genetic test improves the safety of warfarin.